Novartis announced plans to build a flagship manufacturing hub across its North Carolina sites, adding new biologics, sterile packaging and solid‑dose facilities in Durham and Morrisville. The investment is part of a broader $23 billion U.S. infrastructure pledge and is slated to bring roughly 700 direct jobs and over 3,000 supply‑chain positions by 2030. The hub will house end‑to‑end capabilities — biologics production, sterile filling and solid dosage manufacturing — with staged openings targeted for 2027–2028. Novartis said the build supports on‑shoring of cell and gene therapies, radioligand and other advanced modalities, reflecting industry emphasis on domestic resilience for complex biologics. Company leadership framed the initiative as securing supply chains and accelerating patient access to advanced medicines while aligning manufacturing capacity with late‑stage product launches.